The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Research Report 2025
Synopsis
The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market was valued at US$ 9591.9 million in 2023 and is anticipated to reach US$ 24730 million by 2030, witnessing a CAGR of 14.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).
Report Scope
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
Segment by Type
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Segment by Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market was valued at US$ 9591.9 million in 2023 and is anticipated to reach US$ 24730 million by 2030, witnessing a CAGR of 14.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).
Report Scope
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
Segment by Type
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Segment by Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PCR
1.2.3 In-situ Hybridization
1.2.4 Immunohistochemistry
1.2.5 Sequencing
1.2.6 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Neurological Disorders
1.3.4 Cardiovascular Disease
1.3.5 Immunological Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Perspective (2019-2030)
2.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Growth Trends by Region
2.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Region (2019-2024)
2.2.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Region (2025-2030)
2.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics
2.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends
2.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
2.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges
2.3.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Revenue
3.1.1 Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Revenue (2019-2024)
3.1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Players (2019-2024)
3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue
3.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2023
3.5 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Breakdown Data by Type
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Type (2019-2024)
4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Type (2025-2030)
5 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Breakdown Data by Application
5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Application (2019-2024)
5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)
6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)
6.4 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)
7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)
7.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)
8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2019-2024)
8.4 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)
9.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)
9.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)
10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)
10.4 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Qiagen NV
11.1.1 Qiagen NV Company Detail
11.1.2 Qiagen NV Business Overview
11.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.1.5 Qiagen NV Recent Development
11.2 GE Healthcare
11.2.1 GE Healthcare Company Detail
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.2.5 GE Healthcare Recent Development
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Detail
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.3.5 Agilent Technologies Recent Development
11.4 F Hoffman La Roche
11.4.1 F Hoffman La Roche Company Detail
11.4.2 F Hoffman La Roche Business Overview
11.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.4.5 F Hoffman La Roche Recent Development
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Detail
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.5.5 Foundation Medicine Recent Development
11.6 Thermo Fisher Scientific Inc.
11.6.1 Thermo Fisher Scientific Inc. Company Detail
11.6.2 Thermo Fisher Scientific Inc. Business Overview
11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.6.5 Thermo Fisher Scientific Inc. Recent Development
11.7 Leica Biosystems Nussloch GmBH
11.7.1 Leica Biosystems Nussloch GmBH Company Detail
11.7.2 Leica Biosystems Nussloch GmBH Business Overview
11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.7.5 Leica Biosystems Nussloch GmBH Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction
11.8.4 Pfizer Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)
11.8.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
